BIOGEN IDEC (IDP MU) stock market data APIs
€149.3666
1.41(0.9%)
as of December 30, 2025
Try our APIs with
free plan!
BIOGEN IDEC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IDP.MU.
Prev. Close
149.3666
Open
150.781
High
150.9824
Low
149.272
52 wk Range
99.02-157.5
Market Cap
30 257 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News
New
UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026
Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks. Continue Reading
5 Healthcare Themes for Investors to Watch in 2026
Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks. Continue Reading
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why
In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the...
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Biogen Inc. Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
